New pill aims to fight Obesity-Linked inflammation
NCT ID NCT07656727
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called BGE-102 in 160 adults with obesity and heart risk factors. The goal is to see if it lowers inflammation (measured by hsCRP) safely. Participants take either BGE-102 or a placebo daily for 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BGE-102 (oral drug)
What this could lead to
If it works, this could point toward a new way to reduce inflammation and improve heart health in people with obesity.
What could go wrong
This is an early Phase 2 trial with only 160 people over 12 weeks. It may not show meaningful benefits or could have side effects. Success is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 100
RECRUITINGRogers, Arkansas, 72758, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 101
RECRUITINGSan Antonio, Texas, 78240, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 102
RECRUITINGMiami, Florida, 33172, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 103
NOT_YET_RECRUITINGLexington, Kentucky, 40509, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 104
RECRUITINGPort Orange, Florida, 32127, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 105
RECRUITINGSan Juan, 00927, Puerto Rico
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 106
RECRUITINGRockville, Maryland, 20854, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 108
RECRUITINGChandler, Arizona, 85225, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 109
RECRUITINGMaitland, Florida, 32751, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 110
RECRUITINGTucson, Arizona, 85711, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 112
RECRUITINGAustin, Texas, 78759, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 113
RECRUITINGKansas City, Missouri, 64131, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Site 115
RECRUITINGPeoria, Arizona, 85381, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••